Evidence map›Paper›PMID 41441762›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Atroposelective Suzuki-Miyaura Coupling to Form 2-Amino-2'-Hydroxybiphenyls Enabled by sRuPhos.

Hamzah Sharif, Luke A McCall, Matthew G Sanders, Robert J Phipps

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Chiral Spiro-Scaffolded C(spAngewandte Chemie (International ed. in English) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Installing Axial Chirality by Atroposelective C(spJournal of the American Chemical Society · 2026
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hamzah SharifYusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
Luke A McCallYusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
Matthew G SandersOncology Targeted Discovery, Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge, CB2 0AA, UK.
Robert J PhippsYusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.ORCID https://orcid.org/0000-0002-7383-5469

Funding

EPSRC EP/W522120/1
6 · The paper itself

Abstract

Atropisomeric biaryls are increasingly important in molecules of pharmaceutical interest. Asymmetric versions of the Suzuki-Miyaura coupling arguably constitute the most direct and attractive route to these without resorting to wasteful preparative separations or resolution steps. Herein, we report a new chiral phosphine ligand sRuPhos, a sulfonated form of RuPhos, which permits the coupling of unprotected ortho-bromoanilines and ortho-phenolic boronate esters with extremely high ee (up to 99%) to form 2-amino-2'-hydroxybiphenyls. N-alkylation can be accommodated on the aniline nitrogen and sRuPhos is also able to form highly hindered 2,2'-biphenols, which could not be achieved in our previous studies using the related chiral ligand sSPhos. Given the great importance of biaryl atropisomers in medicinal chemistry, as well as the potential utility of the 2-amino-2'-hydroxybiphenyl motif in chiral catalyst design, we anticipate that this reaction will soon find utility and that sRuPhos may be a useful ligand in the development of other asymmetric palladium-catalysed processes.

Indexed as

AtropisomersBiarylsCross‐couplingPalladiumPhosphine

Identifiers

PMID41441762
PMCPMC12910156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.